Help Desk

860-305-6955

Intellectual Property

Protecting our innovations and ideas to drive sustainable growth and competitive advantage.

Advancing Therapeutics Through Strong IP

Phoenix has a broad IP platform with over two dozen novel analogs and two drugs in preclinical development, with Phase I trials planned for 2022-2023 for PPL-138. This provides the company with multiple grant opportunities as well as the flexibility to develop different products for different markets (e.g. acute and chronic pain, addiction therapies, animal therapies, etc.).

The Company’s Current I.P. Estate

Novel Compound PPL-103

A Composition of matter and Methods of synthesis patent for our advanced compound, PPL-103, was filed in December, 2010 and issued in the US in March, 2015 and has since received patent approval in 12 major countries around the world. Patents also cover Use for treatment of opioid and cocaine addiction therapy as well as pain, and Use for treatment of pain in animals.

Nociceptin Compounds

Phoenix also has under license 25 Nociceptin compounds including BU10038, which we now call PPL-138. A composition of matter patent covering all of the compounds was filed in the US and Europe in December, 2014 and issued in the US in May, 2018 and in Europe in November, 2020. It has been validated in the UK, France, Germany, Spain, Italy, Belgium, Netherlands, and Switzerland.

Formulations, process and methods of synthesis as well as details concerning additional NCE variants in development are currently protected as trade secrets. Phoenix PharmaLabs believes its unique compounds potentially offer pain sufferers, whether from acute or chronic conditions, new hope for potent pain relief without addiction or other serious opioid side effects. Additionally, our compounds appear to offer significant potential for development as treatments for opioid and cocaine addictions. We intend to continue to develop new analogs within our portfolio of proprietary molecules.

About Us

Phoenix PharmaLabs welcomes inquiries by organizations seeking a beneficial relationship. Please contact us to explore potential opportunities.

Browse

Articles

Connect
Facebook-f Twitter Instagram

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.

Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.

The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.